BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19088025)

  • 21. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
    Romano MF; Lamberti A; Tassone P; Alfinito F; Costantini S; Chiurazzi F; Defrance T; Bonelli P; Tuccillo F; Turco MC; Venuta S
    Blood; 1998 Aug; 92(3):990-5. PubMed ID: 9680368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
    Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
    Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical assessment of curcumin as a potential therapy for B-CLL.
    Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
    Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.
    Nishioka C; Ikezoe T; Togitani K; Yokoyama A
    Bone Marrow Transplant; 2008 Feb; 41(3):303-9. PubMed ID: 17994120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD40 and B chronic lymphocytic leukemia cell response to fludarabine: the influence of NF-kappaB/Rel transcription factors on chemotherapy-induced apoptosis.
    Romano MF; Lamberti A; Turco MC; Venuta S
    Leuk Lymphoma; 2000 Jan; 36(3-4):255-62. PubMed ID: 10674897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
    Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
    Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway.
    Fernández-Calotti P; Gamberale R; Costas M; Sánchez Avalos J; Geffner J; Giordano M
    Int Immunopharmacol; 2006 May; 6(5):715-23. PubMed ID: 16546701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
    Vargas Núñez JA
    An R Acad Nac Med (Madr); 2014; 131(2):441-56. PubMed ID: 27400564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
    Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
    Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
    Zhong Y; Bakke AC; Fan G; Braziel RM; Gatter KM; Leis JF; Maziarz RT; Huang JZ
    Cytometry B Clin Cytom; 2007 May; 72(3):189-95. PubMed ID: 17226861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
    Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
    J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
    Gamberale R; Fernández-Calotti P; Sánchez-Avalos J; Alberto MF; Geffner J; Giordano M
    Haematologica; 2006 Apr; 91(4):574-6. PubMed ID: 16533725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular biology examination in chronic lymphocytic leukemia].
    Telek B; Rejtó L; Mezei G; Karászi E; Kappelmayer J; Balázs M; Kiss A; Ujj G; Rák K; Udvardy M
    Orv Hetil; 2001 Apr; 142(16):833-7. PubMed ID: 11340945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
    Fernández Calotti P; Galmarini CM; Cañones C; Gamberale R; Saénz D; Avalos JS; Chianelli M; Rosenstein R; Giordano M
    Biochem Pharmacol; 2008 Feb; 75(4):857-65. PubMed ID: 18078872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
    Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
    Fonte E; Apollonio B; Scarfò L; Ranghetti P; Fazi C; Ghia P; Caligaris-Cappio F; Muzio M
    Clin Cancer Res; 2013 Jan; 19(2):367-79. PubMed ID: 23224401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
    Ural AU; Kubar A; Avcu F; Tastan HB; Safali M; Nevruz O; Cetin T
    Clin Exp Dermatol; 2007 Mar; 32(2):151-4. PubMed ID: 17244344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.